Here are the Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Experimental cancer drug daratumumab, efficacy of paxlovid, daratumumab mode of action, daratumumab type of drug, what type of drug is daratumumab, daratumumab research transfusion medicine, daratumumab for cancer treatment.
Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report
Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet. Case Presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly. Conclusions: We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM. © 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.
Authors : De Novellis D.; Zeppa P.; Maffei E.; Giudice V.; Selleri C.; Serio B.
Source : John Wiley and Sons Inc
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1002/cnr2.2149 |
| ISSN | 25738348 |
| Volume | 7 |
You can download the article here
If You have any problem, contact us here